USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ZYGOGEN, LLC
Address: 58 Edgewood Avenue
1st Floor, Room 122
ATLANTA, GA 30303
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $918,939.00 6
SBIR Phase II $3,332,783.00 2

Award List:

Zebrafish Assay for Cholesterol and Lipid Lowering Drugs

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amy L. Rubinstein
Award Amount: $186,760.00
Abstract:
DESCRIPTION (provided by applicant): High levels of low density lipoprotein (LDL), cholesterol and triglycerides have been associated with an increase in cardiovascular disease. Drugs such as cholesterol-lowering statins and triglyceride-lowering fibrates have led to a reduction in coronary heart… More

Zebrafish Lipid Metabolism Assay for Drug Screening

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Amy L. Rubinstein
Award Amount: $1,947,219.00
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease is the number one cause of death in the United States today. High levels of cholesterol and triglycerides have been identified as major contributing factors to heart disease. Furthermore, lipid-lowering drugs such as statins and fibrates… More

Zebrafish Screen for Drug-Induced Long QT & Cyp3A

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Timothy C. Baranowski
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Many therapeutic drugs have been withdrawn from market because they were found to cause Torsade de Pointes (TdP), a rare cardiac arrhythmia that often results in death. Because TdP is associated with prolongation of the QT interval (long QT) on… More

Zebrafish Tauopathy Model for Drug Screening and Target Validation

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amy L. Rubinstein
Award Amount: $153,320.00
Abstract:
DESCRIPTION (provided by applicant): Description: Several neurological disorders, including Alzheimer's disease and frontotemporal dementia with parkinsonism (FTDP) are characterized in part by neurofibrillary tangles made up primarily of the protein tau. While useful mammalian models of tauopathy… More

Zebrafish Assay for Parkinson's Disease Drugs

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amy L. Rubinstein
Award Amount: $161,135.00
Abstract:
DESCRIPTION (provided by applicant): Description: The goal of this research program is to develop a rapid, in vivo assay for screening small molecules for their ability to protect or regenerate neurons in a whole vertebrate organism. In Phase I, dopaminergic neurons in zebrafish embryos, made easily… More

Compound Screening in Z-Tag Zebrafish Angiogenesis Assay

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric Sandberg
Award Amount: $163,730.00
Abstract:
DESCRIPTION (provided by applicant): The purpose of this Phase I proposal is to automate the analysis of the Z-Tag angiogenesis assay and to screen a small collection of compounds for their potential angiogenic activity. For the latter, we propose to screen two sets of compound libraries. First, a… More

Z-Tag for Measuring Cardiac Contractility and Cardiac Rhythmicity

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter M. Eimon
Award Amount: $153,994.00
Abstract:
DESCRIPTION (provided by applicant): A major concern regarding drugs in development is cardiac toxicity. Commonly, drugs in development can cause changes to cardiac contractility, the force with which the heart beats, and cardiac rhythmicity, resulting in toxic side effects. The purpose of this… More

Compound Screening in Z-Tag Zebrafish Angiogenesis Assay

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Peter M. Eimon
Award Amount: $1,385,564.00
Abstract:
DESCRIPTION (provided by applicant): Pathological angiogenesis, the growth of new blood vessels during a disease state, contributes to over 70 diseases, including cancer. The proposed studies are a Phase II SBIR grant application focused on the preclincal development of novel anti- angiogenic small… More